Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sionna Therapeutics (SION) Depreciation & Amortization (CF) (2024 - 2026)

Quarterly results put Depreciation & Amortization (CF) at $154000.0 for Q1 2026, down 23.0% from a year ago — trailing twelve months through Mar 2026 was $506000.0 (down 36.67% YoY), and the annual figure for FY2025 was $647000.0, down 7.57%.

Sionna Therapeutics has reported Depreciation & Amortization (CF) over the past 3 years, most recently at $154000.0 for Q1 2026.

  • Depreciation & Amortization (CF) reached $154000.0 in Q1 2026 per SION's latest filing, up from $152000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $200000.0 in Q1 2024 and bottomed at $100000.0 in Q2 2025.
  • Median Depreciation & Amortization (CF) over the past 3 years was $199000.0 (2024), compared with a mean of $167222.2.
  • Peak annual rise in Depreciation & Amortization (CF) hit 0.0% in 2025, while the deepest fall reached 50.0% in 2025.
  • Over 3 years, Depreciation & Amortization (CF) stood at $199000.0 in 2024, then fell by 23.62% to $152000.0 in 2025, then increased by 1.32% to $154000.0 in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for SION at $154000.0 in Q1 2026, $152000.0 in Q4 2025, and $100000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - 1,395.22
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 55.90 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 123.20 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 13.55 Mn
10 Sionna Therapeutics 1.87 Bn 1.87 Bn - 154,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 154,000.00
Mar 31, 2026 154,000.00
Dec 31, 2025 152,000.00
Dec 31, 2025 152,000.00
Sep 30, 2025 100,000.00
Sep 30, 2025 100,000.00
Jun 30, 2025 100,000.00
Jun 30, 2025 100,000.00
Mar 31, 2025 200,000.00
Mar 31, 2025 200,000.00
Dec 31, 2024 199,000.00
Dec 31, 2024 199,000.00
Sep 30, 2024 200,000.00
Sep 30, 2024 200,000.00
Jun 30, 2024 200,000.00
Jun 30, 2024 200,000.00
Mar 31, 2024 200,000.00
Mar 31, 2024 200,000.00